Qnasl is a drug owned by Teva Branded Pharmaceutical Products R And D Llc. It is protected by 5 US drug patents filed from 2013 to 2019. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 21, 2031. Details of Qnasl's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10188811 | Nasal spray device |
Oct, 2031
(6 years from now) | Active |
| US7780038 | Dispensing apparatus with dosage counter |
Jan, 2027
(1 year, 9 months from now) | Active |
| US5776432 | Beclomethasone solution aerosol formulations |
Jul, 2015
(9 years ago) |
Expired
|
| US5683677 | Medicinal aerosol formulations |
Nov, 2014
(10 years ago) |
Expired
|
| US5605674 | Medicinal aerosol formulations |
Feb, 2014
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qnasl's patents.
Latest Legal Activities on Qnasl's Patents
Given below is the list of recent legal activities going on the following patents of Qnasl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jul, 2022 | US10188811 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Feb, 2022 | US7780038 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Jan, 2019 | US10188811 |
| Recordation of Patent Grant Mailed Critical | 29 Jan, 2019 | US10188811 |
| Issue Notification Mailed Critical | 09 Jan, 2019 | US10188811 |
| Application Is Considered Ready for Issue Critical | 07 Dec, 2018 | US10188811 |
| Dispatch to FDC | 07 Dec, 2018 | US10188811 |
| Issue Fee Payment Received Critical | 05 Dec, 2018 | US10188811 |
| Issue Fee Payment Verified Critical | 05 Dec, 2018 | US10188811 |
| Response to Reasons for Allowance | 05 Dec, 2018 | US10188811 |
FDA has granted several exclusivities to Qnasl. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Qnasl, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Qnasl.
Exclusivity Information
Qnasl holds 2 exclusivities. All of its exclusivities have expired in 2017. Details of Qnasl's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2015 |
| New Strength(NS) | Dec 17, 2017 |
Several oppositions have been filed on Qnasl's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Qnasl's generic, the next section provides detailed information on ongoing and past EP oppositions related to Qnasl patents.
Qnasl's Oppositions Filed in EPO
Qnasl has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 22, 2016, by Frkelly. This opposition was filed on patent number EP11779089A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11779089A | Jan, 2016 | FRKelly | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Qnasl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qnasl's family patents as well as insights into ongoing legal events on those patents.
Qnasl's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qnasl's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 21, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qnasl Generics:
There are no approved generic versions for Qnasl as of now.
Alternative Brands for Qnasl
There are several other brand drugs using the same active ingredient (Beclomethasone Dipropionate) as Qnasl. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Norton Waterford |
| ||
| Teva Branded Pharm |
|
About Qnasl
Qnasl is a drug owned by Teva Branded Pharmaceutical Products R And D Llc. Qnasl uses Beclomethasone Dipropionate as an active ingredient. Qnasl was launched by Teva Branded Pharm in 2014.
Approval Date:
Qnasl was approved by FDA for market use on 17 December, 2014.
Active Ingredient:
Qnasl uses Beclomethasone Dipropionate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate ingredient
Dosage:
Qnasl is available in aerosol, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.04MG/ACTUATION | AEROSOL, METERED | Prescription | NASAL |
| 0.08MG/ACTUATION | AEROSOL, METERED | Prescription | NASAL |